<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="allergy-and-immunology" lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher">JOHS</journal-id>
<journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
<journal-title-group>
<journal-title>Journal of HealthCare Sciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">2231-2196</issn>
<issn pub-type="opub">0975-5241</issn>
<publisher>
<publisher-name>Radiance Research Academy</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">275</article-id>
<article-id pub-id-type="doi">http://dx.doi.org/10.52533/JOHS.2024.40501</article-id>
<article-id pub-id-type="doi-url"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Allergy and Immunology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Lifestyle Modification and Medical Treatment of Long QT Syndrome
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Alharbi</surname>
<given-names>Mishari</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ibrahim</surname>
<given-names>Islam</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alzahrani</surname>
<given-names>Sultan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hamdi</surname>
<given-names>Fahad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dause</surname>
<given-names>Wesam</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alshammakh</surname>
<given-names>Mohammed</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aun</surname>
<given-names>Rakan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Howladar</surname>
<given-names>Mohannad</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laban</surname>
<given-names>Bayan</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Almalki</surname>
<given-names>Abdulrahman</given-names>
</name>
</contrib>
</contrib-group>
<pub-date pub-type="ppub">
<day>30</day>
<month>05</month>
<year>2024</year>
</pub-date>
<volume>4</volume>
<issue>5</issue>
<fpage>195</fpage>
<lpage>200</lpage>
<permissions>
<copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
<copyright-year>2009</copyright-year>
<license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<p>Long QT Syndrome (LQTS) is a genetic or acquired cardiac disorder characterized by a prolonged QT interval on an electrocardiogram, predisposing individuals to life-threatening arrhythmias and sudden cardiac death. Management of LQTS involves both lifestyle modifications and pharmacological treatments to mitigate risks and enhance patient outcomes. Lifestyle interventions include avoiding strenuous physical activities, especially swimming, and managing emotional stress to prevent arrhythmic triggers. Dietary modifications, such as maintaining adequate levels of potassium and magnesium, are essential to stabilize the heart__ampersandsign#39;s electrical activity. On the pharmacological front, beta-blockers like propranolol and nadolol are the mainstay treatments, effectively reducing heart rate and adrenergic stimulation, thus minimizing arrhythmic events. Sparings where beta-blockers are insufficient, additional medications like mexiletine, and potassium-sparing diuretics are used to manage the condition. High-risk patients benefit from implantable cardioverter-defibrillators (ICDs), which provide immediate intervention during severe arrhythmic episodes. Combining lifestyle changes with pharmacological treatments offers a comprehensive approach to LQTS management, significantly lowering the incidence of arrhythmias and improving overall patient prognosis. Patient education and regular follow-up are crucial to ensure adherence to treatment plans and timely adjustments. Advances in genetic testing facilitate personalized medicine, allowing for tailored treatment strategies based on individual genetic profiles. This integrated approach enhances the effectiveness of LQTS management, providing a holistic solution to a complex cardiac condition.
</p>
</abstract>
<kwd-group>
<kwd>Long QT Syndrome</kwd>
<kwd> arrhythmias</kwd>
<kwd> lifestyle modifications</kwd>
<kwd> pharmacological treatments</kwd>
<kwd> genetic testing</kwd>
</kwd-group>
</article-meta>
</front>
</article>